Gary D. Glick,Shomir Ghosh,William R. Roush,Edward James Olhava
申请号：
US16703974
公开号：
US20200157097A1
申请日:
2019.12.05
申请国别(地区):
US
年份:
2020
代理人:
摘要：
This disclosure features compounds of Formula I, or a pharmaceutically acceptable salt thereof:in which R1, R2, R3, and R4 are as defined herein. These compounds are modulators of NLRP3, which are useful, e.g., for treating a condition, disease or disorder in which a decrease in NLRP3 activity (e.g., a condition, disease or disorder associated with repressed or impaired NLRP3 signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
